Together, these results emphasize that distinct PD-L1 regulatory networks operate in latent versus active TB, supporting the need for separate therapeutic strategies: e.g., targeting STAT1/3, IRF1, and FOXP1 for ATB, and CDAN1, TCOF1, and LMO2 for LTBI reactivation prevention. This evidence concerns the gene LMO2 and tuberculosis.